Serological prevalence of Sars-Cov-2 infection among chronic Myeloid Leukemia patients undergoing Tyrosine Kinase inhibitor treatment in Italy (COVID-19-HEM study)
Bonifacio M, Binotto G, Tiribelli M, Miggiano MC, Trawinska MM, Scaffidi L, Di Bona E, Damiani D, Velotta V, Ceccarelli G, Pierdomenico E, Loschirico M, Dubbini MV, Cordioli M, Ruggeri M, Fanin R, Semenzato G, Tacconelli E, Pizzolo G, Krampera M
Background: Clinical course of the novel Coronavirus (SARS-CoV-2) Disease 2019 (COVID-19) is extremely heterogeneous, and infected individuals may be asymptomatic or develop acute respiratory manifestations. Elderly people and patients with pre-existing comorbidities, including malignancies, may be at higher risk due to their immunological impairment. On the other hand, still limited evidence suggests that some target drugs used to treat hematological cancers, including tyrosine kinase inhibitors (TKI), may have a direct antiviral action or an indirect immunomodulatory effect on the abnormal inflammatory host response to SARS-CoV-2.